Login to Your Account



Regenerx enrolls first patient in RGN-259 phase III for eye disease

By Michael Fitzhugh
Staff Writer

Monday, September 21, 2015
Less than a week after enrolling the first patient in a phase IIb/III test of its therapeutic eye drops for dry eye syndrome, Regenerx Biopharmaceuticals Inc. has enrolled the first participant in a phase III study of the therapy, RGN-259, for the potential treatment of neurotrophic keratopathy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription